Toggle Main Menu Toggle Search

Open Access padlockePrints

Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34+ progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia

Lookup NU author(s): Professor Konstantinos Stellos

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2016 Elsevier Ireland Ltd Background and aims Hypercholesterolaemia is associated with a reduced number of circulating progenitor cells, a defect that is restored by statin therapy. We studied the effect of rosuvastatin monotherapy or its combination with omega-3 polyunsaturated fatty acids (ω-3 PUFAs) on progenitor cell number and function in patients with mixed dyslipidaemia. Methods Fifty patients with mixed dyslipidaemia and fifty-five normolipidaemic, apparently healthy, age- and sex-matched volunteers participated in the study. Patients were randomized to receive a daily dose of either 40 mg rosuvastatin (R group, n = 26) or 10 mg rosuvastatin plus 2 g of ω-3 PUFAs (R + O group, n = 24). The number of circulating CD34+ and CD34+/KDR+ progenitor cells as well as the number of colony-forming units-endothelial cells (CFU-ECs) at 10 days of culture were assessed at baseline and 3 months post-treatment. Results The number of CD34+ and CD34+/KDR+ cells per 10,000 leukocytes as well as the number of CFU-ECs were significantly lower in both patient groups compared with healthy volunteers (all p = 0.03). A 3-month treatment with either R or R + O significantly increased circulating CD34+ and CD34+/KDR+ cells as well as the number of CFU-ECs compared with baseline (all p = 0.03). Importantly, the increase in the above parameters was inversely correlated with therapy-induced reduction in lipid parameters in both patient groups. Conclusions Patients with mixed dyslipidaemia exhibit low numbers of circulating CD34+ and CD34+/KDR+ cells as well as CFU-ECs in culture, a defect restored by 3-month treatment with either high-rosuvastatin dose or a combination of low-rosuvastatin dose with ω-3 PUFAs. The pathophysiological meaning of our results regarding the increased cardiovascular risk in these patients remains to be established.


Publication metadata

Author(s): Chantzichristos VG, Agouridis AP, Moutzouri E, Stellos K, Elisaf MS, Tselepis AD

Publication type: Article

Publication status: Published

Journal: Atherosclerosis

Year: 2016

Volume: 251

Pages: 240-247

Online publication date: 01/07/2017

Acceptance date: 29/06/2016

ISSN (print): 0021-9150

ISSN (electronic): 1879-1484

Publisher: Elsevier Ireland Ltd

URL: https://doi.org/10.1016/j.atherosclerosis.2016.06.047

DOI: 10.1016/j.atherosclerosis.2016.06.047

PubMed id: 27415612


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share